Abstract 2059P
Background
Two decades ago medication related osteonecrosis of the jaw (MRONJ) was first described in oncology pts receiving BMAs. Pre-existing dental disease is the main initiating factor for MRONJ. Dental disease is the commonest global non-communicable disease. We assessed the impact of integrating a dental oncology service for all incident pts prescribed BMAs.
Methods
A dental clinic was established in March 2022 collocated with a cancer centre and all pts receiving BMAs were assessed by an oral surgeon prior to BMA administration and all necessary dental treatment was completed.
Results
120 pts included (66% female), 66 were <65 years, were treated over 1 year. 82 pts had metastatic disease. Early stage breast cancer (N=35), metastatic breast cancer (N=36), prostate cancer (N=24), and other malignancies (N=25) were represented in this cohort. 118 pts were planned for intravenous zoledronate and 2 were planned for denosumab. 117 pts were deemed dentally fit to commence their BMA. 29 pts were current smokers, and 24 pts wore dentures. 45 pts had a current dental complaint on presentation, for which 31 complaints related to pain and infection. Assessment of barriers to dental services; 20 pts live alone, 42 pts were not registered with a dentist, and 51 hadn’t seen their dentist in ≥3 yrs. 8 pts had intraoral smoking related changes, and moderate dysplasia was identified in 1 pt following a biopsy. The Decayed, Missing and Filled Teeth (DMFT) index median score was 18, and mean DMFT score was 19. 88 pts had a periodontal status of ≥Stage 2 Grade B which demonstrated longstanding and active periodontal disease. The mean bleeding on probing score was 35% and 75 pts had a high Caries Risk Assessment score. 65 pts required an operative dental procedure. 33 pts received a dental restoration, of which 16 pts required a median of 2 dental restorations. 58 pts had teeth extracted, of whom 37 had a median of 3 teeth extracted.
Conclusions
This oncology cohort had poor engagement with dentistry and had a high burden of dental disease prior to BMA treatment. The data highlights their dental treatment needs prior to BMA treatment and the requirement for proactive dental integration by the oncology team. Dental care should be an integral part of multidisciplinary cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CiSA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06